Getting your ADCs to the clinic: Consideration for early stage development
About This Event
The development of existing or novel monoclonal antibodies as drug-conjugates to increase the targeted clinical effect of these proteins has rapidly increased in recent years. Over 30 antibody–drug conjugates (ADCs) are being tested in the clinic in a range of oncology indications.
SMi's masterclass hosted by PAREXEL International will discuss ADCs which are being tested in the clinic in a range of oncology indications. In the absence of specific guidance on the development of ADCs, this workshop aims to help participants understand the CMC issues during the development, with a particular focus on the assessment and control of the quality of such products.
Category: Conferences
Timing: 8:30 am to 1:30 pm.
Price: £599
Artists / Speakers: Parexel International, Isabel Zwart, Alex Bloom.